GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » Liabilities-to-Assets

Oncopeptides AB (OSTO:ONCO) Liabilities-to-Assets : 0.78 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Oncopeptides AB's Total Liabilities for the quarter that ended in Dec. 2024 was kr189.91 Mil. Oncopeptides AB's Total Assets for the quarter that ended in Dec. 2024 was kr244.19 Mil. Therefore, Oncopeptides AB's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 was 0.78.


Oncopeptides AB Liabilities-to-Assets Historical Data

The historical data trend for Oncopeptides AB's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Liabilities-to-Assets Chart

Oncopeptides AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.52 0.24 0.76 0.78

Oncopeptides AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 1.04 0.57 0.58 0.78

Competitive Comparison of Oncopeptides AB's Liabilities-to-Assets

For the Biotechnology subindustry, Oncopeptides AB's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Liabilities-to-Assets falls into.


;
;

Oncopeptides AB Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Oncopeptides AB's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Liabilities-to-Assets (A: Dec. 2024 )=Total Liabilities/Total Assets
=189.907/244.192
=0.78

Oncopeptides AB's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 is calculated as

Liabilities-to-Assets (Q: Dec. 2024 )=Total Liabilities/Total Assets
=189.907/244.192
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncopeptides AB  (OSTO:ONCO) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Oncopeptides AB Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncopeptides AB Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.